Thorne HealthTech shares findings of collaborative trial with Mayo Clinic

Thorne HealthTech shared significant positive findings as a result of a collaborative trial with Mayo Clinic and HealthTech Connex, "The effects of a dietary supplement on brain function and structure in Junior A ice hockey players: a prospective randomized trial." The results are now available on Medrxiv. The double-blinded, placebo-controlled trial measured the brain function of 30 ice hockey players over the course of their season. The trial was led by Mayo Clinic’s Dr. Michael Stuart who was the Principal Investigator. The purpose of the study was to determine whether a nutritional supplement – designed to address specific mechanisms of action associated with head impact – could favorably affect those functions over the course of a hockey season. Participants went through baseline brain function testing at the beginning of the season, then consumed either Thorne’s SynaQuell or a placebo daily for the duration of their season. At the end of the study, the same brain function tests were repeated and compared. The full study and results are expected to be available later this year.